ECSP982523A - Sal tartrato de un dipeptido sustituido - Google Patents

Sal tartrato de un dipeptido sustituido

Info

Publication number
ECSP982523A
ECSP982523A ECSP982523A ECSP982523A EC SP982523 A ECSP982523 A EC SP982523A EC SP982523 A ECSP982523 A EC SP982523A EC SP982523 A ECSP982523 A EC SP982523A
Authority
EC
Ecuador
Prior art keywords
compound
tartaric acid
useful
acid salt
osteoporosis
Prior art date
Application number
Other languages
English (en)
Inventor
Bruce Allen Lefker
Philip Albert Carpino
Jardine Paul A Dasilva
Jerry Anthony Murry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP982523 priority Critical patent/ECSP982523A/es
Publication of ECSP982523A publication Critical patent/ECSP982523A/es

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a la sal de ácido (L)-tartárico o de la 2-amino-N-{1-2,4-difluoro-benciloximetil)-2-oxo-2- [3-oxo-3a-piridin -2-ilmetil-2-(2,2,2-trifluoro-etil)-2,3,3aA, 6,7-hexahidro-pirazolo [4,3-c] piridin -5-il] etil}-2-metil-propionamida, la cual es un secretagogo de la hormona de crecimiento endógena. En otro aspecto, esta invención proporciona determinados productos intermedios que son útiles para la síntesis del compuesto anterior. La sal del ácido (L)-tartárico del compuesto de está invención es útil para el tratamiento y/o prevención de la osteoporosis, resistencia a la insulina y otros trastornos o enfermedades asociadas con la diferencia de hormona del crecimiento. La sal del ácido (L)-tartárico del compuesto de la presente invención es también útil para el tratamiento de la osteoporosis cuando se usa en combinación con: un compuesto bisfosfonato, estrógenos, Premarin y opcionalmente progesterona, un agonista o antagonista de estrógenos o calcitonina. Además,la presente invención se refiere a procedimientos que comprenden la administración de un agonista alfa-2-adrenérgico y de la sal del ácido (L)-tartárico del compuesto de esta invención.
ECSP982523 1998-06-08 1998-06-08 Sal tartrato de un dipeptido sustituido ECSP982523A (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP982523 ECSP982523A (es) 1998-06-08 1998-06-08 Sal tartrato de un dipeptido sustituido

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP982523 ECSP982523A (es) 1998-06-08 1998-06-08 Sal tartrato de un dipeptido sustituido

Publications (1)

Publication Number Publication Date
ECSP982523A true ECSP982523A (es) 1999-01-26

Family

ID=42043444

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP982523 ECSP982523A (es) 1998-06-08 1998-06-08 Sal tartrato de un dipeptido sustituido

Country Status (1)

Country Link
EC (1) ECSP982523A (es)

Similar Documents

Publication Publication Date Title
CO4810383A1 (es) Sal tartrato de un dipeptido sustituido
Mohan et al. Comparison of bone formation responses to parathyroid hormone (1-34),(1-31), and (2-34) in mice
US8076316B2 (en) Steroid compounds and formulations
JP4486258B2 (ja) ヒト副甲状腺ホルモンの改変、調製および使用
JP2632754B2 (ja) 脳内グルタミン酸遊離抑制剤
Gozes et al. Stearyl-norleucine-vasoactive intestinal peptide (VIP): a novel VIP analog for noninvasive impotence treatment
US7521528B2 (en) Conformationally constrained parathyroid hormone (PTH) analogs with lactam bridges
HU213098B (en) Process for producing decapeptides antagonistic to hormone for releazing lutheinizing-hormone and pharmaceutical compositions containing them as active components
EP0748817A3 (en) Parathyroid hormone derivatives and their use
US7795220B2 (en) Conformationally constrained parathyroid hormones with alpha-helix stabilizers
US7910544B2 (en) Conformationally constrained parthyroid hormone (PTH) analogs
US7799757B2 (en) Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents
BR0100946A (pt) Metabólitos de hexahidropirazolo[4,3-c] piridina
JP2002060348A (ja) 身体機能低下の治療のための成長ホルモン分泌促進物質の使用
Horiuchi et al. A multiresponse parathyroid hormone assay: An inhibitor has agonist properties in vivo
KLEIN-NULEND et al. Comparison of the Effects of Synthetic Human Parathyroid Hormone (PTH)-(l–34)-Related Peptide of Malignancy and Bovine PTH-(l–34) on Bone Formation and Resorption in Organ Culture
ECSP982523A (es) Sal tartrato de un dipeptido sustituido
KR970004039B1 (ko) 점막 투여시 흡수 촉진제로서의 시클릭 펩티드
Saggese et al. Combined treatment with growth hormone and gonadotropin-releasing hormone analogues in children with isolated growth hormone deficiency
Escobar et al. Persistence of autonomous ovarian activity after discontinuation of therapy for precocious puberty in McCune-Albright syndrome
Dresner‐Pollak et al. Evaluation in vivo of a potent parathyroid hormone antagonist:[Nle8, 18, D‐Trp12, Tyr34] bPTH (7–34) NH2
EP1121113A1 (en) Methods for regulating bone formation
Garcia et al. Separate binding sites for intact PTH 1-84 and synthetic PTH 1-34 in canine kidney
D’Souza The parathyroid hormone family of ligands and receptors
CN110234334B (zh) 肌肉萎缩抑制组合物